



# Drug Coverage Decision for BC PharmaCare

## About PharmaCare

BC PharmaCare is a publicly funded drug plan that helps B.C. residents pay for most prescription drugs and pharmacy services, and some medical devices and supplies.

## Details of Drug Reviewed

<b>Drug</b>	<b>ravulizumab</b>
Brand name	Ultomiris®
Dosage form(s)	10 mg/mL and 100 mg/mL concentrate for solution for intravenous infusion
Manufacturer	Alexion Pharma GmbH
<b>Submission type</b>	<b>New Submission</b>
Indication reviewed	For the treatment of adult patients with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG)
Canada's Drug and Health Technology Agency (CADTH) Reimbursement Reviews (CRR)	CRR recommended: <b>Do Not Reimburse</b> . Visit the CADTH website for <a href="#">details</a> .
Drug Benefit Council (DBC)	Ravulizumab for gMG was reviewed by the Ministry and did not undergo a review by the DBC as the CRR recommended not to list for the treatment of gMG.
<b>Drug Coverage Decision</b>	<b>Non-benefit</b>
Date	April 17, 2024
Reason(s)	<p><b>Drug coverage decision is consistent with the CADTH recommendation</b></p> <ul style="list-style-type: none"> <li>CADTH stated that the sponsor trial (CHAMPION) did not provide evidence of the efficacy or harms of ravulizumab compared to relevant comparators (e.g., rituximab, immunoglobulin, plasma exchange)</li> <li>Patients with AChR antibody-positive gMG generally respond well to standard of care (SoC) treatment with corticosteroids and immunosuppressive therapies. A minor subset of patients do not</li> </ul>

	<p>respond well to SoC leading to an unmet need for these patients with refractory disease.</p> <ul style="list-style-type: none"> <li>• CADTH concluded that the efficacy of ravulizumab to fill the unmet need in refractory patients is unknown as the CHAMPION trial did not require patients to be refractory to SoC prior to initiation of ravulizumab</li> <li>• The CADTH economic review concluded that ravulizumab is not cost-effective at the submitted price.</li> <li>• The pan-Canadian Pharmaceutical Alliance (pCPA) did not pursue negotiations with the manufacturer for this product for the gMG indication.</li> </ul>
--	---

### The drug review process in B.C.

A manufacturer submits a request to the Ministry of Health (the Ministry).

An independent group called the [Drug Benefit Council \(DBC\)](#) gives advice to the Ministry by considering:

- whether the drug is safe and effective
- advice from a national group called [Canada's Drug and Health Technology Agency \(CADTH\)](#)
- what the drug costs and whether funding it provides good value to the province
- ethical considerations of covering and not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes a BC PharmaCare coverage decision by taking into account:

- existing BC PharmaCare policies, programs and resources
- the evidence-informed advice of the DBC
- drugs already covered by BC PharmaCare that treat similar medical conditions
- the overall cost of covering the drug

Visit [BC PharmaCare](#) and [Drug reviews](#) for more information.

**This document is intended for information only.**

It does not take the place of advice from a physician or other qualified health care provider.